Status:
TERMINATED
Real World Pharmacokinetics of Immune Checkpoint Inhibitors
Lead Sponsor:
Radboud University Medical Center
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rationale: Real-world pharmacokinetic data from cancer patients treated with immune checkpoint inhibitors (ICIs) are sparse. Moreover, pharmacokinetic parameters may be associated with response to ICI...
Eligibility Criteria
Inclusion
- Treatment with immune checkpoint inhibitors (atezolizumab (Tecentriq®), avelumab (Bavencio®), cemiplimab (Libtayo®), durvalumab (Imfinzi®), ipilimumab (Yervoy®), nivolumab (Opdivo®) and pembrolizumab (Keytruda®))
- Willingness and ability to provide written informed consent
- Age 18 years or older
Exclusion
- n/a (real-world)
Key Trial Info
Start Date :
September 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2023
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04833075
Start Date
September 15 2021
End Date
May 15 2023
Last Update
May 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboudumc
Nijmegen, Gelderland, Netherlands, 6525 GA